Summary: Featuring articles on romosozumab or alendronate for fracture prevention, Ebola RNA persistence in semen of survivors, Ebola vaccines, glecaprevir and pibrentasvir for HCV, the sustainability of the blood supply, and reovirus infection in celiac disease; a review article on delirium; a case report of a girl with failure to thrive; and Perspective articles on the first FDA approval agnostic of cancer site, on misdirections in informed consent, and on voluntary site accreditation.
